This month we are increasing our ambition and reviewing 2 articles: the PIETHO trial, and the TOPCoat trial. Everyone will then have access to the three major trials for thrombolysis in submassive PE present on WikEM.
If you missed last month, we read the MOPETT Trial where thrombolysis in moderate PEs appeared safe and decreased pulmonary hypertension. PIETHO focuses on hemodynamic improvement after thrombolysis and TOPCoat has a large composite outcome that includes some patient centered characteristics.